GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Salarius Pharmaceuticals
Salarius is a biotech company focused on epigenetics and the development of targeted therapies for rare cancers such as sarcoma. Its stock price is highly volatile, as the company's value depends entirely on the progress of clinical trials for its key candidates, which will determine its future.
Share prices of companies in the market segment - Cancer cure
Salarius Pharmaceuticals is an oncology company developing drugs targeting epigenetic enzymes to treat various types of cancer. We've categorized the company as a Cancer Treatment company. The chart below shows how investors view innovative approaches to targeted therapy.
Broad Market Index - GURU.Markets
Salarius Pharmaceuticals is an oncology company developing drugs to treat cancer by targeting epigenetic mechanisms. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SLRX - Daily change in the company's share price Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its oncology drugs.
Daily change in the price of a set of shares in a market segment - Cancer cure
Salarius Pharmaceuticals is a biopharmaceutical company developing cancer treatments targeting epigenetic mechanisms. Oncology is a highly volatile sector. The chart below reflects average fluctuations in this industry, providing context for assessing the risks and potential of SLRX shares.
Daily change in the price of a broad market stock, index - GURU.Markets
Salarius Pharmaceuticals is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Salarius Pharmaceuticals
Salarius Pharmaceuticals' year-to-date performance is a story about the development of its targeted oncology drugs. Its 12-month market cap is entirely dependent on clinical trial data. The success of its epigenetic drugs could offer a new approach to treating difficult-to-treat cancers, which is its primary research bet.
Annual dynamics of market capitalization of the market segment - Cancer cure
As an early-stage biotech company, Salarius is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Salarius Pharmaceuticals is a biotech company whose value is based on the hope of developing a new cancer drug. Its year-over-year performance relative to the market isn't a reflection of business processes, but a speculative bet on clinical trial success. The chart is a series of sharp movements driven by news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Salarius Pharmaceuticals
Salarius is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its targeted drugs triggers an immediate and strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Oncology biotech is a sector where early clinical data can determine a company's fate. Its market capitalization dynamics, shown in the chart, reflect this high degree of risk. Developers like Salarius Pharmaceuticals are conducting their research in this environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Salarius Pharmaceuticals is an early-stage oncology company. Its shares exist in a world of their own: their price rises and falls based on research data, paying little attention to overall market trends. The chart illustrates this disconnect.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Salarius Pharmaceuticals
Shares of Salarius Pharmaceuticals, a clinical-stage oncology company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their targeted drugs. The chart below is a prime example of how short-term scientific data and investor expectations shape value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Salarius Pharmaceuticals is a clinical-stage oncology company. Its shares are teetering on the edge of anticipation of trial results. Any news, positive or negative, can trigger sharp price movements. The chart clearly demonstrates how its dynamics are detached from the broader pharmaceutical sector and driven by its own scientific cycle.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Salarius Pharmaceuticals is a biotech company whose fate depends on scientific data. This chart clearly demonstrates how out of sync its weekly performance can be with the broader market. A single clinical trial announcement can cause massive swings while the S&P 500 remains stagnant.
Market capitalization of the company, segment and market as a whole
SLRX - Market capitalization of the company Salarius Pharmaceuticals
Salarius Pharmaceuticals' valuation on the chart is a pure bet on its scientific platform in epigenetics for cancer treatment. This clinical-stage biotech's market cap is entirely dependent on trial results. The dynamics illustrate a binary outcome: either a breakthrough in oncology or failure.
SLRX - Share of the company's market capitalization Salarius Pharmaceuticals within the market segment - Cancer cure
Salarius Pharmaceuticals's market share in oncology reflects its focus on epigenetics, a cutting-edge approach to cancer treatment. Its market share is based solely on the potential of its clinical developments, targeting cancer types for which there are currently few effective treatments.
Market capitalization of the market segment - Cancer cure
The chart below is a barometer of the biotech sector focused on oncology epigenetics. Salarius Pharmaceuticals is one of the developers in this cutting-edge field. The dynamics in the chart reflect the overall risks and hopes associated with the search for fundamentally new approaches to cancer treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the hope for a new approach to cancer treatment. Salarius Pharmaceuticals' market cap reflects investors' faith in its epigenetic drugs. The company's performance is a rollercoaster of clinical trials and expectations, as it attempts to carve out a small but valuable stake in the global oncology industry.
Book value capitalization of the company, segment and market as a whole
SLRX - Book value capitalization of the company Salarius Pharmaceuticals
The book value of clinical-stage Salarius Pharmaceuticals is determined by its scientific potential. The chart below reflects the financial valuation of its intellectual property for drugs targeting epigenetic mechanisms in cancer. The dynamics demonstrate how the company is investing in developing its most important asset—science.
SLRX - Share of the company's book capitalization Salarius Pharmaceuticals within the market segment - Cancer cure
For Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company, its tangible assets are limited to laboratories. The chart shows its modest share of physical infrastructure, emphasizing that its primary value at this stage lies in intellectual property, not manufacturing facilities.
Market segment balance sheet capitalization - Cancer cure
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Salarius, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Salarius Pharmaceuticals develops cancer drugs that target epigenetics—gene "switches." The company's assets are not factories, but intellectual capital and clinical trial data. The chart shows the material resources devoted to this attempt to "reprogram" cancer cells.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage oncology company. Its market value is a valuation of its scientific platform. Investors are betting on its ability to develop a new, effective cancer drug, which creates a huge gap with its book value.
Market to book capitalization ratio in a market segment - Cancer cure
Salarius Pharmaceuticals is a biotech company developing targeted therapies for cancer treatment. Its value depends entirely on the success of its drugs in clinical trials. This chart shows how its market valuation is a bet on the future and is significantly disconnected from its current tangible assets.
Market to book capitalization ratio for the market as a whole
Salarius Pharmaceuticals is a biopharmaceutical company developing cancer treatments. The company's market valuation, as shown in this chart, is based almost entirely on the potential of its scientific developments and patents, rather than on its current assets. The dynamics reflect investor expectations for clinical trial results.
Debts of the company, segment and market as a whole
SLRX - Company debts Salarius Pharmaceuticals
Salarius Pharmaceuticals, a clinical-stage biotech, uses raised capital to fund its oncology research. This chart shows how the company spends investor funds to conduct expensive clinical trials of its drugs, the only path to potential approval and commercialization.
Market segment debts - Cancer cure
Salarius Pharmaceuticals is a clinical-stage biotech company developing cancer treatments. Its operations are entirely dependent on external financing. This chart shows how its debt policy (or lack thereof) reflects the high risk of its developments and its reliance on equity capital to conduct costly clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Salarius Pharmaceuticals
GT Biopharma, like many companies in the immuno-oncology sector, is racing to develop breakthrough cancer treatments. This process is burning through enormous amounts of cash. This chart shows the extent to which its expensive clinical trials are financed by debt, a measure of the financial risk to potential success.
Market segment debt to market segment book capitalization - Cancer cure
Salarius Pharmaceuticals is a clinical-stage biotech developing cancer treatments that target epigenetics. This chart plots its debt load against the overall market capitalization of the oncology sector. It shows how the company funds its cutting-edge, yet risky, research while relying on external capital.
Debt to book value of all companies in the market
Salarius Pharmaceuticals is a clinical-stage biotech company developing cancer treatments. Its success depends entirely on its research results and ability to attract financing. This market debt chart provides insight into the overall availability of capital for such risky but potentially breakthrough research projects.
P/E of the company, segment and market as a whole
P/E - Salarius Pharmaceuticals
For Salarius Pharmaceuticals, a clinical-stage oncology company, the P/E ratio is not a useful metric. The company has no profit, and its valuation on this chart is arbitrary. The intrinsic value is a speculative bet on the success of its clinical trials and the potential of future cancer drugs.
P/E of the market segment - Cancer cure
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare and difficult-to-treat cancers, particularly sarcomas. The company focuses on epigenetic regulation. This chart shows the average valuation for the oncology sector, reflecting how investors assess the risks and potential of small biotechs with innovative approaches.
P/E of the market as a whole
Salarius Pharmaceuticals is a biopharmaceutical company developing cancer treatments that target epigenetic mechanisms. This cutting-edge approach has the potential to be effective across a wide range of tumor types. This risk appetite chart helps understand how investors value early-stage, science-intensive companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Salarius Pharmaceuticals
Salarius Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare cancers in children and adults. This graph reflects market expectations regarding the success of its clinical trials. Future revenue depends entirely on trial results, regulatory approval, and the commercial potential of its drugs.
%20P%2FE%20Salarius%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Salarius-Pharmaceuticals&v=1772646667965 "Chart of the company's future (projected) P/E Salarius Pharmaceuticals")
Future (projected) P/E of the market segment - Cancer cure
Salarius Pharmaceuticals is a clinical-stage biotech company developing cancer treatments. This chart doesn't reflect current earnings, but rather compares investor expectations. It shows how the market views the scientific potential and success rate of its drug candidates compared to other oncology startups.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772646668084 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cancer therapies. For such companies, access to funding is a matter of survival. This chart, reflecting overall market optimism, is a key indicator of investor risk appetite, which determines Salarius's ability to raise capital for research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772646668115 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer treatments. Its financial performance is measured by R&D expenses, not revenue. This chart illustrates a typical biotech scenario, where investment in research is key to creating future value through successful clinical trials.
Profit of companies in the market segment - Cancer cure
Salarius Pharmaceuticals is a biotech company developing targeted drugs for the treatment of cancer, particularly sarcomas and blood cancers. This chart, showing overall sector profitability, reflects the high stakes in oncology. Success in Salarius's clinical trials could not only lead to a breakthrough in treatment but also have a profound impact on the entire industry.
Overall market profit
While this chart reflects revenues from existing businesses, Salarius Pharmaceuticals' value is created in the lab. The company develops cancer treatments, and its future depends on the results of clinical trials. It's an example of a biotech company whose trajectory is determined by scientific breakthroughs rather than general economic cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Salarius Pharmaceuticals
Salarius Pharmaceuticals is a biotechnology company developing cancer treatments. The future profit projections presented here are speculative and entirely dependent on clinical trial results. Analysts' expectations are based on scientific data, drug potential, and potential partnerships with pharmaceutical giants.
%20profit%20of%20the%20company%20Salarius%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Salarius-Pharmaceuticals&v=1772646668180 "Graph of future (projected) profit of the company Salarius Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Cancer cure
Salarius Pharmaceuticals is a biopharmaceutical company developing targeted therapies for the treatment of rare cancers in children and adults. This chart shows future revenue projections for the entire oncology sector. It allows one to assess how the company's niche strategy aligns with overall financial expectations from breakthroughs in cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772646668196 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Salarius Pharmaceuticals is a clinical-stage biotech company developing cancer treatments. Its value is driven by research progress. This chart, which shows overall market sentiment, is critical. During periods of optimism, investors are more inclined to fund high-risk but potentially breakthrough projects like Salarius's.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772646668212 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biotech developing targeted therapies for cancer. For a company with virtually no revenue, this chart reflects hope. It shows a valuation based solely on investors' faith in the scientific potential of its developments and the future commercial success of its drugs.
P/S market segment - Cancer cure
Salarius Pharmaceuticals is a biotech company specializing in the development of epigenetic drugs for the treatment of rare and difficult-to-treat cancers. The company's value is based on the potential of its scientific developments. This chart reflects how investors estimate revenue (or its future potential) in the oncology sector, reflecting expectations for Salarius's clinical programs.
P/S of the market as a whole
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer treatments that target epigenetic pathways. Its valuation is dependent on the success of clinical trials. This chart, which displays the average valuation, demonstrates how biotech companies' valuations are driven by future potential rather than current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biotech company developing cancer treatments. This chart shows investors' valuation relative to its potential future revenue, not current revenue. It reflects their confidence in the scientific success of its developments and the commercial potential of drugs that could hit the market within a few years.
%20P%2FS%20Salarius%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Salarius-Pharmaceuticals&v=1772646668422 "The graph of the company's future (projected) P/S Salarius Pharmaceuticals")
Future (projected) P/S of the market segment - Cancer cure
Salarius Pharmaceuticals is a clinical-stage biotech company developing targeted therapies for rare cancers. The chart shows the average estimated future sales in the cancer treatment sector. It helps understand how investors view Salarius's scientific potential and risks compared to other companies developing new oncology therapies.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772646668464 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Salarius Pharmaceuticals (SLRX) is a clinical-stage biotech company developing drugs to treat rare cancers. Their future depends solely on the success of clinical trials. This chart of general economic expectations bears no relation to their valuation, which is determined by scientific data, not market trends.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772646668498 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biotech company focused on fighting cancer. Its revenue comes not from sales, but from licensing agreements and partnerships with major pharmaceutical companies. This chart reflects the receipt of milestone payments for research achievements, which validates the value of its scientific developments.
Sales of companies in the market segment - Cancer cure
Salarius Pharmaceuticals is a clinical-stage oncology company developing targeted therapies. It currently has no sales revenue. Its future revenue will depend on the success of its lead candidate, seclaklinib, in treating sarcomas and other cancers, demonstrating its focus on epigenetics.
Overall market sales
Salarius Pharmaceuticals is a biotech company developing cancer treatments. Its success depends on clinical trial results, not economic cycles. However, the overall economic climate, reflected in this chart, influences the overall investment climate and the funding available for risky but socially significant research in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biotechnology company developing targeted therapies for rare cancers. Since the company does not yet have commercial products, this chart represents a long-term forecast reflecting analysts' confidence in the scientific and commercial potential of its developments.
%20sales%20of%20the%20company%20Salarius%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Salarius-Pharmaceuticals&v=1772646668655 "Schedule of future (projected) sales of the company Salarius Pharmaceuticals")
Future (projected) sales of companies in the market segment - Cancer cure
Salarius Pharmaceuticals is a biopharmaceutical company developing targeted therapies for rare cancers. This chart presents the outlook for the oncology drug sector. It reflects the overall level of investment in cancer research and the demand for new treatments, which creates the environment for Salarius's clinical development.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772646668675 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important for Salarius Pharmaceuticals. The company develops cancer treatments. Its ability to fund long-term clinical trials depends on capital inflows into the industry, which increase during periods of overall economic strength.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772646668706 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biotechnology company developing targeted therapies for cancer treatment. This chart reflects its focus on investing in research. Future profitability is entirely dependent on the success of clinical trials, regulatory approvals, and commercialization of its innovative drugs.
Market segment marginality - Cancer cure
Salarius Pharmaceuticals is a biopharmaceutical company developing cancer treatments that target epigenetic pathways. Its profitability depends on the success of clinical trials and the potential commercialization of its targeted therapies. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the scientific and commercial potential of Salarius's developments.
Market marginality as a whole
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer treatments. Its future depends entirely on the success of its research and its ability to raise capital. This chart reflects the overall investment climate and market risk appetite, which are crucial factors for funding long and expensive biotech development projects.
Employees in the company, segment and market as a whole
Number of employees in the company Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biotech company developing cancer treatments. This graph reflects a compact team of scientists and clinicians. This small staff is typical for R&D companies, where each employee possesses high levels of expertise. Growth will signal a move to later, larger-scale trials.
Share of the company's employees Salarius Pharmaceuticals within the market segment - Cancer cure
Salarius Pharmaceuticals develops targeted therapies for rare and aggressive cancers. Its team consists of highly specialized oncology scientists. This chart shows the company's share of the total number of researchers in its narrow therapeutic area. This reflects its scientific potential and focus on creating medicines for patients with limited options.
Number of employees in the market segment - Cancer cure
Salarius Pharmaceuticals is a biopharmaceutical company developing cancer treatments that target epigenetic pathways. This chart, illustrating employment in the oncology research sector, is an indicator of the intensity of innovation. The growing number of scientists in this field indicates intense competition and massive investment in the search for new cancer treatments.
Number of employees in the market as a whole
Salarius Pharmaceuticals is a biotech company developing cancer drugs. Its success depends on long-term investment in science. This overall employment chart reflects the health of the economy, which allows both private investors and large foundations to finance the expensive clinical trials necessary to bring life-saving drugs to market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Salarius Pharmaceuticals (SLRX)
Salarius is a biopharmaceutical company focused on treating rare cancers. This chart shows a classic example of valuing "intellectual capital." The company may have a small staff, but its market value is entirely dependent on the potential of its developments and patents. Each employee essentially "maintains" extremely valuable intellectual property.
%20of%20the%20company%20Salarius%20Pharmaceuticals%20(SLRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Salarius-Pharmaceuticals-SLRX&v=1772646669104 "Chart of market capitalization per employee (in thousands of dollars) of the company Salarius Pharmaceuticals (SLRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Salarius Pharmaceuticals is a clinical-stage biotech company developing cancer drugs. Its greatest asset is not its factories or staff, but its intellectual property and the potential of its future drugs. This chart helps us understand the enormous value the market can place on the work of a small team of scientists compared to that of large pharmaceutical companies.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772646669109 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Salarius Pharmaceuticals is a clinical-stage biotech developing cancer treatments. Its market capitalization is based entirely on its scientific potential. This chart shows the extremely high valuation per employee, typical for biotech, as investors are betting on a future breakthrough from a small team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772646669164 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Salarius Pharmaceuticals (SLRX)
Salarius Pharmaceuticals is a biotech company developing targeted drugs for the treatment of cancer, particularly sarcoma and blood cancers. This is pure R&D. This chart isn't about profit, but rather about the capital burn rate. It shows how much the company invests (negative profit) per scientist to advance drug candidates through expensive clinical trials.
%20Chart%20Salarius%20Pharmaceuticals%20(SLRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Salarius-Pharmaceuticals-SLRX&v=1772646669170 "Company Profit Per Employee (in thousands of dollars) Chart Salarius Pharmaceuticals (SLRX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Salarius Pharmaceuticals is a biopharmaceutical company focused on cancer treatment. For such companies, profit per employee is often negative during the development stage. This graph is important for its dynamics: as the drugs become commercialized, it should increase, reflecting the transition from costly research to revenue generation from sales and licensing agreements with pharmaceutical giants.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772646669193 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Salarius Pharmaceuticals (SLRX) is a biopharmaceutical company developing targeted therapies for rare cancers. It's a classic clinical-stage biotech (R&D). Its staff consists of highly paid scientists. There is no profit. This metric is negative and reflects the "cost" of one employee, who creates a potential future asset—a new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772646669221 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Salarius Pharmaceuticals (SLRX)
Salarius Pharmaceuticals is a biotech company developing cancer treatments. Revenue can be minimal during clinical trials. This chart serves as a starting point, as if a single drug is successful, its sales will drive explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Salarius-Pharmaceuticals-SLRX&v=1772646669238 "Sales chart per company employee Salarius Pharmaceuticals (SLRX)")
Sales per employee in the market segment - Cancer cure
Salarius is a clinical-stage biotech company developing targeted cancer therapies. They have no commercial products. This chart clearly illustrates their R&D burnout. The productivity of their team of elite scientists is measured not by sales, but by progress in clinical trials, which generates future value.
Sales per employee for the market as a whole
Evolv Technologies (EVLV) solves public safety problems with AI-powered screening systems that detect weapons without disrupting the flow of people. It's a business that combines sophisticated hardware (scanners) and software (AI). This chart shows how the company is scaling its technology. As the number of installations grows, software subscription revenue (SaaS) should grow faster than the number of technicians and engineers, increasing overall efficiency.
Short shares by company, segment and market as a whole
Shares shorted by company Salarius Pharmaceuticals (SLRX)
Salarius Pharmaceuticals (SLRX) is a clinical-stage biotech developing cancer drugs. This chart shows the number of short positions. "Shorts" here are direct bets that the company's clinical trials will fail, which is the most likely outcome for the vast majority of revenue-depleting biotechs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Salarius-Pharmaceuticals-SLRX&v=1772646669370 "Short Shares Chart for the Company Salarius Pharmaceuticals (SLRX)")
Shares shorted by market segment - Cancer cure
Salarius (SLRX) is a biotech developing targeted drugs for cancer treatment. Like the entire industry, their path is risky. The chart below shows the overall short interest in the oncology biotech sector. It's a barometer of how much investors believe in the success of risky clinical trials and new platforms.
Shares shorted by the overall market
Salarius Pharmaceuticals is a clinical-stage biotech developing cancer drugs. This chart illustrates the overall market pessimism. When fear prevails, investors are reluctant to finance the "burning" of cash. They are selling off SLRX shares, fearing the company will not have enough capital to complete expensive oncology trials amid market panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Salarius Pharmaceuticals (SLRX)
This chart for Salarius is a barometer of hope in the treatment of rare cancers. The company is developing inhibitors (Seclidemstat) to combat sarcoma and other tumors. "Overbought" levels (above 70) arise from positive data from early-phase trials. A halt in a key trial (as happened) or clinical failures immediately send the stock plummeting (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Salarius-Pharmaceuticals-SLRX&v=1772646669478 "RSI 14 indicator chart for the company's stock Salarius Pharmaceuticals (SLRX)")
RSI 14 Market Segment - Cancer cure
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare cancers, particularly sarcoma. This is high-risk R&D. This chart reflects the overall sentiment in the oncology sector and helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Salarius Pharmaceuticals (SLRX) is a biotech company specializing in oncology. Its value depends almost entirely on the success of clinical trials and investor sentiment in the sector. This chart shows the overall market "temperature." When the market is euphoric (overbought), investors are willing to fund risky developments. When panic sets in (oversold), capital for SLRX becomes scarce.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SLRX (Salarius Pharmaceuticals)
Salarius Pharmaceuticals is a biotech company focused on developing targeted therapies for the treatment of cancer (epigenetics), including sarcoma. This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SLRX-Salarius-Pharmaceuticals&v=1772646669654 "A chart showing analyst consensus forecasts for the expected stock price. SLRX (Salarius Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price SLRX (Salarius Pharmaceuticals)
Salarius is a biotech company developing cancer treatments (inhibitors) that target epigenetics—the mechanism by which genes are "read." This chart measures the gap between the current price and the consensus target price. It shows how much confidence experts have in this complex yet cutting-edge R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SLRX-Salarius-Pharmaceuticals&v=1772646669668 "A chart showing the difference between the consensus forecast and the actual stock price. SLRX (Salarius Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Salarius is an R&D biotech developing "epigenetic" drugs (LSD1 inhibitors) for cancer treatment. This is high-risk R&D. This chart reflects analysts' overall expectations for the entire cancer treatment sector. It shows whether experts believe in the success of junior biotechs in oncology.
Analysts' consensus forecast for the overall market share price
Salarius Pharmaceuticals is a biotech company specializing in the development of targeted therapies for cancer treatment. This chart shows the overall market "risk appetite." For SLRX, a high-risk clinical-stage company, overall market optimism (the rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Salarius Pharmaceuticals
Salarius is a biotech cancer hunter. It's an R&D company developing targeted drugs (small molecules) for the treatment of rare cancers (sarcoma) and blood cancers. This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their chances of approval.
AKIMA Market Segment Index - Cancer cure
Salarius Pharmaceuticals is an oncology company focused on rare cancers, particularly in children (sarcoma). They develop drugs that attack specific cancer drivers. This chart compares their composite index to the sector, showing how this highly specialized yet important mission compares to other biotechs.
The AKIM Index for the overall market
Salarius Pharmaceuticals is a biotech company developing epigenetic drugs to treat rare cancers (Ewing's sarcoma). This chart, which reflects the market average, provides a macro backdrop. It helps assess how SLRX, a scientific story in pediatric oncology, compares to overall economic trends.
